| Name | Title | Contact Details |
|---|
Chartwell Pennsylvania is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We hold market leading positions in advanced wound care, ostomy care, continence and critical care and infusion devices. Our customers depend on our advanced technologies to help reduce potential complications of skin breakdown and infection, and they rely on our products and services to help manage their conditions every day. Meeting their needs is what motivates us and is a source of tremendous pride for our nearly 9,500 employees who are based in more than 110 countries worldwide. At ConvaTec, we exist to improve the lives of the people we touch. We are committed to helping people with chronic health conditions lead the life they want – giving them more mobility, confidence and freedom. Our vision is to be recognised as the most respected and successful MedTech company, worldwide. To achieve this, we drive for excellence in all that we do – anticipating and addressing our customers` needs with advanced technologies and best-in-class products and services. Our values-based culture helps drive our success. Caring for People: We are passionate about improving people`s lives and put people at the centre of everything we do. Driving Innovation and Excellence: We are dedicated to finding innovative solutions that anticipate and address our customers` needs and to delivering best-in-class execution. Earning Trust: We earn trust by delivering quality products and services that our customers can rely on. Our personal actions underpin this trust – we do what we say we will do.
Bilcare Research is a Delaware City, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliance Surgical Distributors is a Redlands, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Procyrion is developing the first catheter-deployed circulatory assist device intended for long-term use. The Procyrion device will be the first minimally invasive tool for cardiologists to treat over 1M NYHA Class III and early class IV heart failure (HF) patients in the US who have few therapeutic options. In partnership with Texas Heart Institute, Procyrion is currently conducting preclinical testing of the Procyrion device.